Will pCR and Pembro Redefine Breast Cancer Treatment?
Archived series ("HTTP Redirect" status)
Replaced by: Medscape Oncology
When?
This feed was archived on January 22, 2018 19:33 (
Why? HTTP Redirect status. The feed permanently redirected to another series.
What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 181366298 series 9914
Content provided by Medscape Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medscape Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr Laura Esserman discusses the ground-breaking I-SPY breast cancer research platform and its most 'exciting' results to date, indicating that pembrolizumab triples pCR in TNBC.
…
continue reading
149 episodes
Share
))
